RxDoctor Payments Data

Jonathan Scharfstein, MD

Cardiovascular Disease · Mayfield Hgts, OHNPI 1730192360

Payments from drug & device makers

$3,664in general payments, 2019–2025

Across 94 payments — averaging $38.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Boston Scientific$222
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$190
  • AstraZeneca$137
  • Novartis$128
  • Johnson & Johnson$85
  • plus $515 from 12 others

What the payments were for

  • Travel & lodging$1,06929%
  • Food & beverage$2,59571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,664 in reported general payments places this provider in the 60th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$146,624
Medicare patients
1,204
Services billed
2,993

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis11$293,024
EliquisApixaban111$138,091
JardianceEmpagliflozin43$52,386
Repatha SureclickEvolocumab35$37,369
EntrestoSacubitril/Valsartan26$35,674
XareltoRivaroxaban18$15,521
Repatha PushtronexEvolocumab12$10,703
Ezetimibe182$6,642
Atorvastatin Calcium273$3,268
Metoprolol Succinate166$2,421
Rosuvastatin Calcium132$2,046
Isosorbide Mononitrate ErIsosorbide Mononitrate57$841
Lisinopril130$824
Metoprolol Tartrate92$711
Nitroglycerin58$434

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$17$431,115122 claims
NovartisEntresto$128$35,67426 claims
Johnson & JohnsonXarelto$85$15,52118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Mayfield Hgts

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →